A long acting, injectable two drug regimen developed by Pfizer and GSK joint venture ViiV Healthcare has similar efficacy to daily, three drug antiretroviral in adults living with HIV, according to data from two Phase 3 trials.
The two drug regimen, injected every four weeks was non-inferior to a standard of care three drug combo in the 48 week long FLAIR and ATLAS trials involving 566 men and women, and 616 men and women living with HIV.
![[column] Toekomst tijdschriften glanst als nooit tevoren](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/happy-couple-in-t-shirts-reading-newspaper-while-h-2024-11-10-00-13-23-utc-1-80x60.jpg)
![[column] MarketingAffairs 17: Marketing als oplossing](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/asian-seo-manager-writing-on-glass-with-illustrati-2024-11-17-23-11-51-utc-1-80x60.jpg)
